Table 1.
Baseline characteristics of the patients.
| Characteristic | Chemosensitive patients (n = 21) | Chemoresistant patients (n = 54) |
|---|---|---|
| Age at randomization — yr | ||
| Median | 53 | 58 |
| Range | 41–70 | 37–82 |
| Male sex — no (%) | 10 (48) | 36 (67) |
| TNM stage — no (%) | ||
| III | 7 (33) | 23 (43) |
| IV | 14 (67) | 31 (57) |
| First-line platinum-based chemotherapy — no. (%) | ||
| mFOLFIRINOX | 18 (86) | 42 (78) |
| GemOx | 1 (5) | 7 (13) |
| GP | 2 (10) | 5 (9) |
| Rounds of mFOLFIRINOX | ||
| Median | 11 | 3.5 |
| Range | 6–12 | 1–6 |
| Rounds of GemOx | ||
| Median | 8 | 3 |
| Range | 8 | 2–4 |
| Rounds of GP | ||
| Median | 7 | 4 |
| Range | 6–8 | 3–4 |
| Germline BRCA or PALB2 mutation — no. (%) | ||
| BRCA1 | 0 (0) | 0 (0) |
| BRCA2 | 2 (10) | 0 (0) |
| PALB2 | 2 (10) | 0 (0) |